Genospectra Announces the Acquisition of Panomics
News Feb 14, 2006
Genospectra, Inc. has announced that it is merging with Panomics, Inc. Commenting on the merger, Dr. Frank Witney, Genospectra's CEO said, "Genospectra and Panomics have long discussed the remarkable synergy between our two businesses."
"We are impressed with the way that Panomics has quickly established a broad portfolio of innovative products for proteomics analysis and live-cell assays."
"We are convinced that when united with our PQB initiative, the combined entity will be well positioned for rapid growth since it will serve a wide range of customers in both academic and for-profit end markets."
By combining Panomics portfolio with Genospectra's products and technologies for Parallel Quantitative Biology, the new company will provide an integrated pipeline of products in the functional biology and drug discovery space.
The mission of the combined entity is to provide PQB products for basic life science research and critical applications such as cell signaling, RNAi-mediated gene silencing and high performance assays, clinical biomarker discovery and predictive toxicology.
With plans to launch a series of innovative products to study FFPE and blood biomarkers, protein-protein interactions, cell signaling and gene silencing, the new company has already established targeted goals.
Dr. Jason Li, former CEO of Panomics added, "We are excited to combine our efforts to drive functional biology programs with products that extend from cellular delivery and gene modulation to gene and protein expression, and ultimately through innovative live cell assays."
Ron Hahn of Battelle Ventures, Genospectra board member, and lead investor of Genospectra's Series C financing said, "This merger makes excellent sense for Genospectra's and Panomics' employees, customers and investors."
"By leveraging the strengths of two synergistic portfolios in complementary markets, it enables the combined company to grow rapidly and take its place among world-class life science reagents companies."
The companies will be merged under the name Panomics, with Dr. Witney of Genospectra as the new company's CEO and Dr. Li, founder and former CEO of Panomics, in the role of the new company's Chief Operating Officer.
In conjunction with the acquisition, Genospectra closed a $12.2 Million financing, with Sigma-Aldrich joining as a new strategic investor and partner, and certain existing investors and affiliates of both companies also participating.
A key strategic goal of the Sigma-Aldrich relationship is to help drive the development of the next generation of live cell biosensors and cell based assays.
George Lee of Amkey Ventures joined the Genospectra Board of Directors, which will become the new company's board. Following integration, the new Panomics will be headquartered at Genospectra's existing facilities in Fremont, California.
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
Gene Regulator May Contribute to Protein Pileup in Exfoliation GlaucomaNews
Researchers are seeking factors that contribute to protein pileup in exfoliation glaucomaREAD MORE
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE